Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says

This article was originally published in The Pink Sheet Daily

Executive Summary

DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.
Advertisement

Related Content

Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
Novartis Looks To Recent Launches To Bolster Diovan Against Generic Onslaught
Novartis Appoints Specialty Drug Division Head To Lead North American Pharma Unit
Drug Development Chief Departs Beleaguered Novartis
Novartis To Launch Galvus In EU With Lower Dosing Recommendation
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
Novartis Asks CHMP To Modify European Galvus Label To Recommend Lower Dose
Novartis To Resubmit Galvus In Mid-2009
Novartis To Resubmit Galvus In Mid-2009

Topics

Advertisement
UsernamePublicRestriction

Register

PS066740

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel